Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Stopped Amgen decided to discontinue study because of a business decision and not because of safety reasons

Conditions

• Diffuse Large B-cell Lymphoma(DLBCL)
• Mantle Cell Lymphoma (MCL)
• Follicular Lymphoma (FL)

Interventions

• DRUG: AMG 562

Sponsor

Amgen